

# **ETHIOPIA Support for Rotavirus Vaccine**

### This Decision Letter sets out the Programme Terms of a Programme.

1.	Country: Ethiopia								
2.	Grant number: 1720-ETH-13b-X / 12-ETH-08a-Y								
3.	Date of Decision Letter: 23 March 2018								
4.	Date of the Partnership Framework Agreement: 23 July 2013								
5.	Programme title: New Vaccine Support (NVS), Rotavirus Routine								
6.	Vaccine type: Rotavirus								
7.	Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule								
8.	Programme duration <sup>1</sup> : 2012 - 2020								
<ol> <li>Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)</li> </ol>									
		2012-2017	2018	2019	2020	Total <sup>2</sup>			
Programme Budget (US\$)		57,731,4713	12,265,000	12,693,000	13,208,500	95,897,971			

- 10. Vaccine introduction grant (in US\$): A VIG of US\$2,469,000 was dibused on 14th August 2013 and US\$ 212,502 returned to Gavi on 16th February 2018.
- 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)4

Type of supplies to be purchased with Gavi funds in each year	2012-2017	2018
Number of Rotavirus vaccines doses		5,902,500
Annual Amounts (US\$)	US\$57,731,471 <sup>5</sup>	US\$12,265,000

- 12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 13. Self-procurement: Not applicable

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

> 2 Chemin des Mines 1202 Geneva. Switzerland

Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50 www.gavi.org info@gavi.org

<sup>&</sup>lt;sup>1</sup> This is the entire duration of the Programme.

<sup>&</sup>lt;sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>&</sup>lt;sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>&</sup>lt;sup>4</sup> This is the amount that Gavi has approved.



# 14. Co-financing obligations: Reference code: 1720-ETH-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020
Number of vaccine doses	630,000	651,000	678,000
Value of vaccine doses (US\$)	US\$1,265,074	US\$1,309,228	US\$1,362,387
Total co-financing payments (US\$) (including freight)	US\$1,306,500	US\$1,352,500	US\$1,407,000

#### 15. Operational support for campaigns: Not applicable

## 16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,

On behalf of Gavi

Hind Khatib-Othman

Third A. Thatil

Managing Director, Country Programmes

23 March 2018